526P Integrin beta-6 (IB6) in focus: Contemporary real-world evidence on prevalence in non-small cell lung cancer (NSCLC)

March 17, 2026ESMO OpenOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research investigates the prevalence of integrin beta-6 (STAS) in patients with non-small cell lung cancer (NSCLC) and its impact on survival outcomes.
Evaluated 252 patients with NSCLC based on the 8th TNM classification.
Analyzed overall survival (OS) and disease-free survival (DFS) associated with STAS positivity.
Compared histological subtypes and their correlation with STAS status.
STAS was present in 58.8% of patients, significantly associated with micropapillary tumors.
STAS positivity linked to higher rates of lymphovascular invasion and N2 lymph node metastasis.
Patients with STAS positivity after sublobar resection had a 50% mortality rate and reduced OS (p < 0.014).

Evidence finds integrin beta-6 prevalence affects outcomes in non-small cell lung cancer, suggesting surgical strategies should consider STAS status.

No takes yet. Share an insight, caveat, or question.

Borgia et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share